Antisense Research and Application

1. Front Matter

   Pages I-XXVI

   PDF

2. Basic Principles of Antisense Therapeutics

   • S. T. Crooke

   Pages 1-50

3. Antisense Medicinal Chemistry

   • P. D. Cook

   Pages 51-101

4. In Vitro Cellular Uptake, Distribution, and Metabolism of Oligonucleotides

   • R. M. Crooke

   Pages 103-140

5. Pharmacokinetic Properties of Phosphorothioates in Animals — Absorption, Distribution, Metabolism and Elimination

   • P. L. Nicklin, S. J. Craig, J. A. Phillips

   Pages 141-168

6. Toxicity of Oligodeoxynucleotide Therapeutic Agents

   • A. A. Levin, D. K. Monteith, J. M. Leeds, P. L. Nicklin, R. S. Geary, M. Butler et al.

   Pages 169-215

7. Pharmacokinetic Properties of Phosphorothioate Oligonucleotides in Humans

   • J. M. Leeds, R. S. Geary

   Pages 217-232

8. Safety and Tolerance of Phosphorothioates in Humans

   • P. J. Schechter, R. R. Martin

   Pages 233-241

9. Immune Stimulation by Oligonucleotides

   • A. M. Krieg

   Pages 243-262

10. Pharmacological Inhibition of Dopaminergic and Other Neurotransmitter Receptors Using Antisense Oligodeoxynucleotides

    • G. Davidkova, B. Weiss

    Pages 263-308

11. Pharmacological Effects of Antisense Oligonucleotide Inhibition of Immediate-Early Response Genes in the CNS

    • B. J. Chiasson, M. O. Hebb, H. A. Robertson

    Pages 309-339

12. Inhibition of G Proteins by Antisense Drugs

    • F. Kalkbrenner, B. Wittig, G. Schultz

    Pages 341-369

13. Use of Antisense Oligonucleotides to Modify Inflammatory Processes

    • C. F. Bennett, T. P. Condon

    Pages 371-393

14. Antisense Oligonucleotides and Their Anticancer Activities

    • D. Fabbro, M. Müller, T. Geiger

    Pages 395-425

15. Pharmacological Activity of Antisense Oligonucleotides in Animal Models of Disease

    • B. P. Monia, N. M. Dean

    Pages 427-443

16. Clinical Antiviral Activities

    • S. L. Hutcherson

    Pages 445-462

17. Antisense Oligonucleotides to Protein Kinase C-α and C-raf Kinase: Rationale and Clinical Experience in Patients with Solid Tumors

    • F. A. Dorr, D. L. Kisner

    Pages 463-476

18. Nucleic Acid Therapeutics for Human Leukemia: Development and Early Clinical Experience with Oligodeoxynucleotides Directed at c-myb

    • A. M. Gewirtz

    Pages 477-497

19. Properties of ISIS 2302, an Inhibitor of Intercellular Adhesion Molecule-1, in Humans

    • W. R. Shanahan Jr.

    Pages 499-524

20. Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animals

    • S. Agrawal, R. Zhang

    Pages 525-543

Antisense technology may result in dramatic changes in the therapy of many diseases and may provide tools to dissect pharmacological processes and to confirm the roles of various genes. In this volume, progress in the understanding of antisense technology and its use in creating new drugs is discussed. Potential caveats, pitfalls and limitations of the technology are also presented. In the next few years the pace at which new molecular targets will be identified will increase exponentially as the sequencing of the human genome and of other genomes proceeds.

• Anti-Sense
• Antisense
• Oligonuclotide
• Pathobiochemie
• Therapie
• dopamine
• medicinal chemistry
• oligoneucleotides
• therapeutics

• ISIS Pharmaceuticals, Inc., Carlsbad Research Center, Carlsbad, USA

  Stanley T. Crooke

Policies and ethics